2023 World Conference on Lung Cancer (Posters)-EP07.02. The Utility of Postoperative ctDNA Detection in Guiding Adjuvant Therapy for Resectable Stage III Non-small Cell Lung Cancer

EP07.02. The Utility of Postoperative ctDNA Detection in Guiding Adjuvant Therapy for Resectable Stage III Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to determine the role of circulating tumor DNA (ctDNA) in guiding adjuvant therapy selection for resectable stage III non-small cell lung cancer (NSCLC) patients. The researchers combined data from four independent cohort studies of NSCLC patients who had undergone surgery. Blood samples were collected for ctDNA detection 3 days to 1 month after surgery. The primary endpoint was relapse-free survival (RFS), and the secondary endpoint was overall survival (OS).<br /><br />Out of the 104 patients assessed, 31 were ctDNA-positive and 73 were ctDNA-negative. In the ctDNA-positive group, patients who received adjuvant therapy had a better RFS compared to those who did not (HR, 0.28, P<0.001). ADT was identified as an independent prognostic factor for recurrence in ctDNA-positive patients. However, in the ctDNA-negative group, there were no significant differences in RFS between patients who received ADT and those who did not (HR, 1.05, P=0.939). There were also no differences in OS between the ADT and non-ADT groups in both the ctDNA-positive and ctDNA-negative groups.<br /><br />The study further demonstrated that the RFS of patients who received chemotherapy-based or tyrosine kinase inhibitor ADT was better than patients who did not receive ADT in the ctDNA-positive group but not in the ctDNA-negative group.<br /><br />In conclusion, postoperative ctDNA detection may serve as a tool to guide adjuvant therapy for stage III NSCLC patients. This can help in personalizing adjuvant treatment and avoiding overtreatment. Overall, this research highlights the potential utility of ctDNA in improving the treatment outcomes of resectable stage III NSCLC patients.

Asset Subtitle

bolin wang

Meta Tag

Speaker bolin wang

Topic Early-Stage NSCLC: New Technology & Innovations

Keywords

circulating tumor DNA

ctDNA

adjuvant therapy

resectable stage III non-small cell lung cancer

NSCLC

relapse-free survival

overall survival

prognostic factor

chemotherapy-based ADT

tyrosine kinase inhibitor ADT